NovaBiotics

NovaBiotics is a clinical-stage biotechnology company specializing in the design and development of first-in-class anti-infective therapies for diseases that are difficult to treat and have significant unmet medical needs. Headquartered in Aberdeen, Scotland, with additional operations in Dublin, Ireland, and Boston, USA, NovaBiotics targets conditions such as onychomycosis (fungal nail infection), cystic fibrosis, and other infections resistant to current treatments. The company serves healthcare providers and patients who require advanced therapeutic options for these challenging conditions.

NovaBiotics operates in the biotechnology and pharmaceutical markets, focusing on antimicrobial resistance and novel therapeutic solutions. Its business model revolves around the research, development, and eventual commercialization of its proprietary drug candidates. Revenue is generated through a combination of licensing agreements, partnerships with larger pharmaceutical companies, and direct sales of its approved therapies.

NovaBiotics has a robust pipeline of products, including Novexatin, a peptide-based treatment for onychomycosis, and Novamycin, a novel antifungal peptide. The company is also repurposing its experimental drug Nylexa for COVID-19 trials, showcasing its adaptability and commitment to addressing urgent healthcare challenges.

Keywords: clinical-stage, biotechnology, anti-infectives, antimicrobial resistance, onychomycosis, cystic fibrosis, peptide therapies, drug development, COVID-19, novel antifungal.